Two cases of uveitis masquerade syndrome caused by bilateral intraocular large B-cell lymphoma

• Main Authors: Jovanović Svetlana, Jovanović Zorica, Paović Jelena, Čeperković-Stanković Vesna, Pešić Snežana, Marković Vujica
• Format: Article
• Language: English
• Published: Military Health Department, Ministry of Defance, Serbia 2013-01-01
• Series: Vojnosanitetski Pregled
• Subjects: eye neoplasms; lymphoma, non-Hodgkin; uveitis; diagnosis, differential
• Online Access: http://www.doiserbia.nb.rs/img/doi/0042-8450/2013/0042-84501312151J.pdf

Introduction. Sometimes it is not easy to clinically recognize subtle differences between intraocular lymphoma and noninfectious uveitis. The most common lymphoma subtype involving the eye is B-cell lymphoma. Case report. We presented two patients aged 59 and 58 years with infiltration of the subretinal space with a large B-cell non-Hodgkin intraocular lymphoma. The patients originally had clinically masked syndrome in the form of intermediate uveitis. As it was a corticosteroid-resistant uveitis, we focused on the possible diagnosis of neoplastic causes of this syndrome. During hospitalization, the neurological symptoms emerged and multiple subretinal changes accompanied by yellowish white patches of retinal pigment epithelium with signs of vitritis, which made us suspect the intraocular lymphoma. Endocranial magnetic resonance imaging established tumorous infiltration in the region of the left hemisphere of the cerebellum. The histopathological finding confirmed the diagnosis of large B-cell non-Hodgkin lymphoma of risk moderate degree, immunoblast - centroblast cytological type. The other patient had clinical chronic uveitis accompanied by yellowish shaped white echographic changes of the retina and localized changes in the level of the subretina. The diagnosis of lymphoma was made by brain biopsy. Conclusion. Uveitis masquerade syndrome should be considered in all patients over 40 years with idiopathic steroid-resistant uveitis. Treatment begun on time can affect the course and improve the prognosis of uveitis masquerade syndrome (UMS) and systemic disease.